Evidence map›Paper›PMID 40164445›Full record

ArticleBMJ open gastroenterology2025

Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial.

Siddharth Singh, Jasmine D Nguyen, David I Fudman, Mark E Gerich, Samir A Shah, David Hudesman, Ryan A McConnell, Dana J Lukin, Ann D Flynn, Caroline Hwang and 25 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05230173 (Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission), which is not on this map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05230173 narecruitingnot on this map

Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission

TypeinterventionalSponsorMayo ClinicRan2022 to 2029Enrolled216ConditionsUlcerative Colitis, Crohn DiseaseArmsPragmatic
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Siddharth SinghDivision of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California, USA sis040@ucsd.edu.ORCID http://orcid.org/0000-0002-2640-7269
Jasmine D NguyenDivision of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California, USA.
David I FudmanUniversity of Texas Southwestern, Dallas, Texas, USA.ORCID http://orcid.org/0000-0001-8618-7635
Mark E GerichDivision of Gastroenterology and Hepatology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.ORCID http://orcid.org/0009-0008-1952-1486
Samir A ShahGastroenterology Associates, Inc, powered by the GI Alliance, Providence, Rhode Island, USA.
David HudesmanNYU Langone Health, New York, New York, USA.ORCID http://orcid.org/0009-0009-8004-7709
Ryan A McConnellPalo Alto Medical Foundation, Palo Alto, California, USA.
Dana J LukinWeill Cornell Medicine, New York, New York, USA.
Ann D FlynnDivision of Gastroenterology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA.ORCID http://orcid.org/0000-0002-7236-3375
Caroline HwangDigestive Health Institute, Hoag Memorial Hospital, Irvine/Newport Beach, California, USA.
Brandon SprungDivision of Gastroenterology and Hepatology, University of Rochester Medical Center, Rochester, New York, USA.ORCID http://orcid.org/0009-0004-3786-5312
Jill K J GaidosSection of Digestive Diseases, Yale University, New Haven, Connecticut, USA.ORCID http://orcid.org/0000-0002-1240-1819
Mark C MattarDivision of Gastroenterology, Department of Medicine, MedStar Georgetown University Hospital, Washington, District of Columbia, USA.
David T RubinMacLean Center for Clinical Medical Ethics, University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, Illinois, USA.
Jana G HashashDivision of Gastroenterology and Hepatology, Mayo Clinic Jacksonville, Jacksonville, Florida, USA.
Mark MetwallySaratoga Schenectady Gastroenterology Associates, Burnt Hills, New York, USA.
Tauseef AliSSM Health Crohn's and Colitis Center, Oklahoma City, Oklahoma, USA.ORCID http://orcid.org/0009-0008-1092-4537
Christopher MaDivision of Gastroenterology and Hepatology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Frank HoentjenDivision of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada.ORCID http://orcid.org/0000-0001-5314-4452
Neeraj NarulaDivision of Gastroenterology, Department of Medicine, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Talat BessissowDivision of Gastroenterology, Montreal General Hospital, McGill University Health Centre, Montreal, Quebec, Canada.ORCID http://orcid.org/0000-0003-2610-1910
Greg RosenfeldDepartment of Medicine, IBD Centre of British Columbia, University of British Columbia, Vancouver, British Columbia, Canada.
Jeffrey D McCurdyDepartment of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Ashwin N AnanthakrishnanDivision of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Raymond K CrossCenter for Inflammatory Bowel and Colorectal Diseases, Melissa L. Posner Institute for Digestive Health & Liver Disease at Mercy Medical Center, Baltimore, Maryland, USA.
Jorge R Rodriguez GaytanDepartment of Medicine, Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, Texas, USA.
Emily-Sophinie GurrolaDivision of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California, USA.
Sagar PatelDivision of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California, USA.ORCID http://orcid.org/0009-0007-8781-8858
Corey A SiegelCenter for Digestive Health, Section of Gastroenterology and Hepatology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA.ORCID http://orcid.org/0000-0002-2240-6605
Gil Y MelmedKarsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical System, Los Angeles, California, USA.
S Alandra WeaverCrohn's & Colitis Foundation, New York, New York, USA.
Sydney PowerDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Guangyong ZouDepartment of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.ORCID http://orcid.org/0000-0001-5773-4185
Vipul JairathDepartment of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.ORCID http://orcid.org/0000-0001-8603-898X
Jason K HouDepartment of Medicine, Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, Texas, USA.

Funding

Comparative effectiveness research in Hispanic patients with inflammatory bowel diseasesR01DK135937 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Siddharth Singh · 2024 to 2026
$1.9M
NIDDK NIH HHS R01 DK135937
6 · The paper itself

Abstract

introductionTargeted immunomodulators (eg, advanced therapies) effectively achieve symptomatic remission in patients with inflammatory bowel disease (IBD). However, ~25%-50% of patients with IBD achieving symptomatic remission with an advanced therapy may have continued endoscopically/radiologically active bowel inflammation, and it is uncertain whether changing alternative advanced therapies in asymptomatic patients with IBD will reduce bowel inflammation and achieve durable deep remission. METHODS AND ANALYSIS: The QUality Outcomes Treating IBD to Target (QUOTIENT) study is an open-label, multicentre, pragmatic, randomised, controlled trial that aims to compare the efficacy and safety of switching to an alternative advanced therapy targeting endoscopic/radiological remission (treat-to-target) versus continuing the initial, or index, advanced therapy, in asymptomatic patients with IBD with moderate-to-severe endoscopic/radiological bowel inflammation. Enrolment is planned for ~250 participants in Canada/USA, randomised 1:1 to switching to alternative advanced therapy or continuing index advanced therapy, and then followed 104 weeks within routine clinical practice. Patient-reported outcomes measure efficacy and quality of life/treatment burden/safety. Primary endpoint is the time from randomisation to treatment failure. ETHICS AND DISSEMINATION: The study is conducted in compliance with the protocol, ICH Good Clinical Practice, applicable regulatory requirements and appropriate review boards/independent ethics committees (approval numbers: Pro00077486; Pro00061437; STUDY00002062; 22-004171; i22-01269; IRB22-0890; IRB_00154397; 2000032384; SHIRB#2022.095-2; STUDY00007146; MMC#2024-18; REB#125290; 17784; Pro00142214; 20240660-01H), with documented written informed consent. Findings will be disseminated through peer-reviewed journals, scientific presentations, and publicly available Patient-Centered Outcomes Research Institute (PCORI) websites, including lay summaries. The Crohn's & Colitis Foundation Education, Support, and Advocacy Department, and our patient advocacy stakeholder, will develop educational and marketing resources to communicate findings to a broad audience (>250 000 patients/caregivers/healthcare professionals). TRIAL REGISTRATION NUMBER: NCT05230173.

Indexed as

Immunomodulating AgentsInflammatory Bowel DiseasesAdultCanadaFemaleHumansMaleMulticenter Studies as TopicPatient Reported Outcome MeasuresPragmatic Clinical Trials as TopicQuality of LifeRemission InductionTreatment OutcomeImmunomodulating AgentsCROHN'S DISEASEIMMUNOTHERAPYINFLAMMATORY BOWEL DISEASE

Identifiers

PMID40164445
PMCPMC11962770

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.